Hui-Wen Lo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2721238/publications.pdf

Version: 2024-02-01

89 papers	7,130 citations	66343 42 h-index	56724 83 g-index
91 all docs	91 docs citations	91 times ranked	10595 citing authors

#	Article	IF	Citations
1	Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression. Cancer Research, 2007, 67, 9066-9076.	0.9	605
2	Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers, 2016, 8, 22.	3.7	476
3	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell, 2005, 7, 575-589.	16.8	463
4	STAT3 Target Genes Relevant to Human Cancers. Cancers, 2014, 6, 897-925.	3.7	398
5	Mechanisms regulating glioma invasion. Cancer Letters, 2015, 362, 1-7.	7.2	269
6	Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell, 2004, 6, 251-261.	16.8	261
7	Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. British Journal of Cancer, 2006, 94, 184-188.	6.4	254
8	Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Research, 2018, 78, 4316-4330.	0.9	233
9	Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators. Clinical Cancer Research, 2008, 14, 6042-6054.	7.0	226
10	Nuclearâ€cytoplasmic transport of EGFR involves receptor endocytosis, importin Î²1 and CRM1. Journal of Cellular Biochemistry, 2006, 98, 1570-1583.	2.6	210
11	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Research and Treatment, 2006, 95, 211-218.	2.5	209
12	Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. Cancer Letters, 2012, 318, 124-134.	7.2	205
13	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Research, 2005, 65, 338-48.	0.9	199
14	Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Current Opinion in Pharmacology, 2007, 7, 367-374.	3.5	188
15	Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes. Molecular Cancer Research, 2010, 8, 232-245.	3.4	163
16	Coâ€regulation of Bâ€Myb expression by E2F1 and EGF receptor. Molecular Carcinogenesis, 2006, 45, 10-17.	2.7	157
17	A Novel Splice Variant of GLI1 That Promotes Glioblastoma Cell Migration and Invasion. Cancer Research, 2009, 69, 6790-6798.	0.9	134
18	Inhibiting TRK Proteins in Clinical Cancer Therapy. Cancers, 2018, 10, 105.	3.7	133

#	Article	IF	Citations
19	EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance. Current Molecular Pharmacology, 2010, 3, 37-52.	1.5	116
20	Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene, 2012, 31, 104-115.	5.9	111
21	Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. Cancer Research, 2016, 76, 4970-4980.	0.9	102
22	Hedgehog Signaling and Truncated GLI1 in Cancer. Cells, 2020, 9, 2114.	4.1	97
23	IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. Frontiers in Oncology, 2022, 12, 866014.	2.8	87
24	Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas. Current Cancer Drug Targets, 2010, 10, 840-848.	1.6	82
25	Hedgehog pathway and GLI1 isoforms in human cancer. Discovery Medicine, 2012, 13, 105-13.	0.5	79
26	Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene, 2018, 37, 2502-2514.	5.9	69
27	EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis. Molecular Cancer, 2011, 10, 26.	19.2	68
28	TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene, 2020, 39, 64-78.	5.9	64
29	The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. Current Genomics, 2010, 11, 238-245.	1.6	63
30	Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discovery Medicine, 2010, 10, 44-51.	0.5	60
31	Cancerâ€Specific Gene Therapy. Advances in Genetics, 2005, 54, 233-255.	1.8	59
32	STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3. Molecular Carcinogenesis, 2013, 52, 959-969.	2.7	57
33	EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Letters, 2010, 294, 101-110.	7.2	55
34	The Human Glutathione S-Transferase P1 Protein Is Phosphorylated and Its Metabolic Function Enhanced by the Ser/Thr Protein Kinases, cAMP-Dependent Protein Kinase and Protein Kinase C, in Glioblastoma Cells. Cancer Research, 2004, 64, 9131-9138.	0.9	54
35	EGFR and HER2 signaling in breast cancer brain metastasis. Frontiers in Bioscience - Elite, 2016, 8, 245-263.	1.8	51
36	Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Research and Treatment, 2019, 175, 553-566.	2.5	51

#	Article	IF	Citations
37	Identification and Functional Characterization of the Human Glutathione S-Transferase P1 Gene as a Novel Transcriptional Target of the p53 Tumor Suppressor Gene. Molecular Cancer Research, 2008, 6, 843-850.	3.4	50
38	Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. Oncogene, 2020, 39, 6589-6605.	5.9	50
39	M-HIFU Inhibits Tumor Growth, Suppresses STAT3 Activity and Enhances Tumor Specific Immunity in a Transplant Tumor Model of Prostate Cancer. PLoS ONE, 2012, 7, e41632.	2.5	49
40	Regulation of Apoptosis by HER2 in Breast Cancer. Journal of Carcinogenesis & Mutagenesis, 2013, 2013, .	0.3	48
41	Staged Stereotactic Radiosurgery for Large Brain Metastases: Local Control and Clinical Outcomes of a One-Two Punch Technique. Neurosurgery, 2018, 83, 114-121.	1.1	48
42	Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Letters, 2019, 448, 11-19.	7.2	47
43	The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. Oncotarget, 2015, 6, 22653-22665.	1.8	46
44	The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. Cancer Letters, 2014, 343, 51-61.	7.2	45
45	Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF. EBioMedicine, 2019, 44, 194-208.	6.1	45
46	Genomic Cloning of hGSTP1*C, an Allelic Human Pi Class Glutathione S-Transferase Gene Variant and Functional Characterization of Its Retinoic Acid Response Elements. Journal of Biological Chemistry, 1997, 272, 32743-32749.	3.4	38
47	Elevated leptin disrupts epithelial polarity and promotes premalignant alterations in the mammary gland. Oncogene, 2019, 38, 3855-3870.	5.9	38
48	Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis. Cancers, 2020, 12, 1827.	3.7	36
49	Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget, 2017, 8, 73947-73963.	1.8	33
50	Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors. Cancer Research, 2004, 64, 1788-1793.	0.9	32
51	EGFR and HER2 signaling in breast cancer brain metastasis. Frontiers in Bioscience - Elite, 2016, 8, 245-263.	1.8	30
52	Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. Frontiers in Oncology, 2020, 10, 615472.	2.8	29
53	Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Research, 2018, 78, 2589-2600.	0.9	26
54	Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2â†'CNTF axis to promote progression of brain metastases. Cancer Letters, 2022, 540, 215726.	7.2	24

#	Article	IF	Citations
55	Identification, Functional Characterization, and Pathobiological Significance of GLI1 Isoforms in Human Cancers. Vitamins and Hormones, 2012, 88, 115-140.	1.7	23
56	Use of non-ionizing electromagnetic fields for the treatment of cancer. Frontiers in Bioscience - Landmark, 2018, 23, 284-297.	3.0	22
57	Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 295-303.	0.8	20
58	Structure of the human allelic glutathione S-transferase-Ï€ gene variant, hGSTP1*C, cloned from a glioblastoma multiforme cell line. Chemico-Biological Interactions, 1998, 111-112, 91-102.	4.0	19
59	Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases. Journal of Neuro-Oncology, 2022, 157, 101-107.	2.9	19
60	Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Clinical Neurology and Neurosurgery, 2016, 151, 73-78.	1.4	18
61	HER2 Phosphorylates and Destabilizes Pro-Apoptotic PUMA, Leading to Antagonized Apoptosis in Cancer Cells. PLoS ONE, 2013, 8, e78836.	2.5	16
62	Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers. Discovery Medicine, 2017, 23, 325-330.	0.5	16
63	Cyclic AMP mediated GSTP1 gene activation in tumor cells involves the interaction of activated CREB-1 with the GSTP1 CRE: A novel mechanism of cellular GSTP1 gene regulation. Journal of Cellular Biochemistry, 2002, 87, 103-116.	2.6	15
64	Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?. Neuroradiology, 2018, 60, 1043-1051.	2.2	15
65	LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer. Breast Cancer Research and Treatment, 2020, 181, 31-41.	2.5	13
66	Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer. Journal of Thoracic Disease, 2012, 4, 639-42.	1.4	11
67	Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. International Journal of Biological Markers, 2019, 34, 90-97.	1.8	10
68	TGLI1 Upregulates Expression of VEGFR2 and VEGF-A, Leading to a Robust VEGF-VEGFR2 Autocrine Loop and Cancer Cell Growth. Cancer Hallmarks, 2013, 1, 28-37.	0.8	10
69	Biology and treatment of metastasis of sarcoma to the brain. Frontiers in Bioscience - Elite, 2016, 8, 233-244.	1.8	9
70	Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 813-819.	1.3	9
71	Leptomeningeal failure in patients with breast cancer receiving stereotactic radiosurgery for brain metastases. Journal of Clinical Neuroscience, 2017, 43, 6-10.	1.5	8
72	Transgenic mouse models of breast cancer. Cancer Letters, 2021, 516, 73-83.	7.2	7

#	Article	IF	Citations
73	Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2. Oncogene, 2020, 39, 7034-7050.	5.9	6
74	NEDD4 degrades TUSC2 to promote glioblastoma progression. Cancer Letters, 2022, 531, 124-135.	7.2	6
75	TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. Cancers, 2021, 13, 2340.	3.7	5
76	Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. Journal of Radiosurgery and SBRT, 2018, 5, 277-283.	0.2	5
77	CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Scientific Reports, 2019, 9, 14385.	3.3	4
78	Survival and Failure Outcomes Predicted by Brain Metastasis Volumetric Kinetics in Melanoma Patients Following Upfront Treatment with Stereotactic Radiosurgery Alone. Cureus, 2017, 9, e1934.	0.5	4
79	Trk receptor tyrosine kinases in metastasis and cancer therapy. Discovery Medicine, 2019, 28, 195-203.	0.5	4
80	The number of prior lines of systemic therapy as a prognostic factor for patients with brain metastases treated with stereotactic radiosurgery: Results of a large single institution retrospective analysis. Clinical Neurology and Neurosurgery, 2018, 165, 24-28.	1.4	3
81	Akt destabilizes p57Kip2: Akt at the converging crossroad?. Cell Cycle, 2013, 12, 870-871.	2.6	2
82	Stereotactic radiosurgery in the treatment of brain metastases from gynecologic primary cancer. Journal of Radiosurgery and SBRT, 2017, 5, 55-61.	0.2	2
83	Brain metastasis prognostic nomograms and brain metastasis velocity: a narrative review. Chinese Clinical Oncology, 2022, 11, 10-10.	1.2	1
84	Clinical Outcomes of Dose Escalated Re-Irradiation in Patients with Recurrent High Grade Glioma. Neuro-Oncology Practice, 0, , .	1.6	1
85	Editorial [Hot topic: Emerging Therapeutic Targets and Agents for Glioblastoma Therapy â€“ Part II (Guest Editor: Hui-Wen Lo)]. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 511-511.	1.7	0
86	BSCI-13. TUMOR-SPECIFIC tGLI1 TRANSCRIPTION FACTOR MEDIATES BREAST CANCER BRAIN METASTASIS VIA ACTIVATING METASTASIS-INITIATING CANCER STEM CELLS AND ASTROCYTES IN THE TUMOR MICROENVIRONMENT. Neuro-Oncology Advances, 2019, 1, i3-i3.	0.7	0
87	54. tGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii11-ii11.	0.7	0
88	Abstract 1979: JAK2/STAT3 and TrkA pathways are frequently co-activated in triple-negative and HER2-enriched breast cancers and the co-activation correlates with an increased potential of metastasis. , 2021, , .		0
89	BSCI-14. tGLI1 is an actionable therapeutic target in breast cancer brain metastases. Neuro-Oncology Advances, 2021, 3, iii4-iii4.	0.7	0